(VIANEWS) – Walker & Dunlop (WD), Kiniksa Pharmaceuticals, Ltd. (KNSA), Lattice Semiconductor Corporation (LSCC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Walker & Dunlop (WD)
28.2% sales growth and 8.1% return on equity
Walker & Dunlop, Inc., through its subsidiaries, originates, sells, and services a range of multifamily and other commercial real estate financing products and services for owners and developers of real estate in the United States. The company offers first mortgage, second trust, supplemental, construction, mezzanine, preferred equity, small-balance, and bridge/interim loans. It also provides multifamily finance for manufactured housing communities, student housing, affordable housing, and senior housing properties under the Fannie Mae's DUS program; and construction and permanent loans to developers and owners of multifamily housing, affordable housing, senior housing, and healthcare facilities. In addition, the company acts as an intermediary in the placement of commercial real estate debt between institutional sources of capital, including life insurance companies, investment banks, commercial banks, pension funds, CMBS conduits, and other institutional investors, as well as owners of various types of commercial real estate. Further, it advises on capital structure; develops the financing package; facilitates negotiations between its client and institutional sources of capital; coordinates due diligence; and assists in closing the transaction. Additionally, the company offers property sales brokerage, underwriting and risk management, and servicing and asset management services. Walker & Dunlop, Inc. was founded in 1937 and is headquartered in Bethesda, Maryland.
Earnings Per Share
As for profitability, Walker & Dunlop has a trailing twelve months EPS of $4.24.
PE Ratio
Walker & Dunlop has a trailing twelve months price to earnings ratio of 17.8. Meaning, the purchaser of the share is investing $17.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.1%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 24.4%, now sitting on 1.07B for the twelve trailing months.
Yearly Top and Bottom Value
Walker & Dunlop’s stock is valued at $75.49 at 20:22 EST, way below its 52-week high of $101.02 and way higher than its 52-week low of $61.06.
Sales Growth
Walker & Dunlop’s sales growth is negative 6.1% for the current quarter and 28.2% for the next.
2. Kiniksa Pharmaceuticals, Ltd. (KNSA)
15.5% sales growth and 81.84% return on equity
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Earnings Per Share
As for profitability, Kiniksa Pharmaceuticals, Ltd. has a trailing twelve months EPS of $3.12.
PE Ratio
Kiniksa Pharmaceuticals, Ltd. has a trailing twelve months price to earnings ratio of 5.1. Meaning, the purchaser of the share is investing $5.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 81.84%.
3. Lattice Semiconductor Corporation (LSCC)
11.3% sales growth and 40.53% return on equity
Lattice Semiconductor Corporation, together with its subsidiaries, develops and sells semiconductor products in Asia, Europe, and the Americas. The company offers field programmable gate arrays that consist of four product families, including the Certus-NX and ECP, MachXO, iCE40, and CrossLink. It also provides video connectivity application specific standard products. In addition, the company licenses its technology portfolio through standard IP and IP core licensing, patent monetization, and IP services. It sells its products directly to end customers, and indirectly through a network of independent manufacturers' representatives and independent distributors. The company primarily serves original equipment manufacturers in the communications and computing, consumer, and industrial and automotive end markets. Lattice Semiconductor Corporation was incorporated in 1983 and is headquartered in Hillsboro, Oregon.
Earnings Per Share
As for profitability, Lattice Semiconductor Corporation has a trailing twelve months EPS of $1.48.
PE Ratio
Lattice Semiconductor Corporation has a trailing twelve months price to earnings ratio of 58.67. Meaning, the purchaser of the share is investing $58.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 40.53%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Lattice Semiconductor Corporation’s EBITDA is 16.08.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.8%, now sitting on 722.86M for the twelve trailing months.
4. Universal Health Services (UHS)
6.1% sales growth and 11.27% return on equity
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments. Its hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric services, pharmacy services, and/or behavioral health services. The company also provides commercial health insurance services; and various management services, which include central purchasing, information, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Earnings Per Share
As for profitability, Universal Health Services has a trailing twelve months EPS of $9.62.
PE Ratio
Universal Health Services has a trailing twelve months price to earnings ratio of 13.32. Meaning, the purchaser of the share is investing $13.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.27%.
